Decentralised trials (DCTs) or virtual trials are those that allow patients to participate in the studies without visiting the clinic site.
The use of DCTs soared following the COVID-19 pandemic after lockdowns were imposed and several restrictions were placed on movement.
Go deeper with GlobalData
GlobalData conducted a survey to assess pre-pandemic DCT use by company role.
Pre-pandemic Decentralised Trial Use by Company Role
The survey found that nearly half (49%) of other contract service providers started using DCTs before the COVID-19 pandemic. It includes CMOs, bioanalysis, training, consulting, Software and digital solution providers for clinical trials.
The adoption rate of virtual trials before coronavirus stood at 42% and 36% for CROs and clinical/ investigator sites, respectively.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe survey also found that only 19% of Pharma/ Biotech and 14% of Government/ Academic Institutes explored DCTs before the pandemic hit the world.
The analysis is based on responses received from the GlobalData Coronavirus Survey -– Pharmaceutical Imports/Exports and Supply Chain, fielded between 04 June and 22 June 2020.
